

MYLAN INC.  
Form 8-K  
July 30, 2010

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549  
FORM 8-K  
CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): July 30, 2010 (July 30, 2010)**

**MYLAN INC.**

(Exact Name of Registrant as Specified in Charter)

**Pennsylvania**  
(State or Other Jurisdiction  
of Incorporation)

**1-9114**  
(Commission  
File Number)

**25-1211621**  
(I.R.S. Employer  
Identification No.)

**1500 Corporate Drive**  
**Canonsburg, PA**  
(Address of Principal Executive Offices)

**15317**  
(Zip Code)

Registrant's telephone number, including area code: **(724) 514-1800**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2 (b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4 (c))
-

**Item 1.01 Entry into a Material Definitive Agreement.**

On July 30, 2010, Mylan Inc. (the Company ) and the guarantors named therein entered into a Purchase Agreement (the Purchase Agreement ) with Goldman, Sachs & Co., as initial purchaser, relating to the sale by the Company of \$300 million aggregate principal amount of the Company s 7.875% Senior Notes due 2020 (the Notes ) at an issue price of 105.5%, or an effective yield to maturity of 7.087%.

The Notes will be issued in a private offering that is exempt from the registration requirements of the Securities Act of 1933 (the Securities Act ) to qualified institutional buyers in accordance with Rule 144A and to persons outside of the U.S. pursuant to Regulation S under the Securities Act. The Notes will be the Company s senior unsecured obligations and will be guaranteed on a senior unsecured basis by certain of the Company s domestic subsidiaries. Subject to customary closing conditions, the sale of the Notes is expected to close on or about August 13, 2010.

The Purchase Agreement contains customary representations, warranties and agreements by the Company and the guarantors. In addition, the Company and the guarantors have agreed to indemnify the initial purchaser against certain liabilities, including liabilities under the Securities Act, or to contribute to payments the initial purchaser may be required to make in respect of those liabilities. Furthermore, the Company and the guarantors have agreed with the initial purchaser not to offer or sell any substantially similar debt securities for a period of 90 days after the closing date without the prior written consent of the initial purchaser.

The Company intends to use the net proceeds of this offering to finance a portion of the \$550 million purchase price for the previously-announced acquisition of all of the equity of Bioniche Pharma Holdings Limited, a privately held, global injectable pharmaceutical company. The closing of this offering will not be conditioned on consummation of the Bioniche Pharma acquisition. If the Bioniche Pharma acquisition is not consummated, the Company intends to use the net proceeds from the offering for general corporate purposes, which may include repayment of indebtedness or business development opportunities.

**Item 8.01. Other Events.**

On July 30, 2010, the Company issued a press release announcing the pricing of the Notes. A copy of the press release is attached hereto as Exhibit 99.1.

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits.

| Exhibit No. | Description                                       |
|-------------|---|
| 99.1        | Press release of Mylan Inc., dated July 30, 2010. |

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

MYLAN INC.

Date: July 30, 2010

By: /s/ John D. Sheehan  
John D. Sheehan  
Executive Vice President and  
Chief Financial Officer

---

**EXHIBIT INDEX**

Exhibit No. Description

99.1 Press release of Mylan Inc., dated July 30, 2010.